万珂提高多发性骨髓瘤干细胞采集的临床研究  

Clinical Research on the Improvement of Autologous Stem Cells Collection in Patients with Multiple Myeloma after Velcade-based Chemotherapy

作　　者：何东[1] 刘志刚[1] 喻琴梅[1] 邝璞[1] 向兵 何川[1] 卢忠平[1] 鲁建春[1] 刘霆[1] 牛挺[1] 

机构地区：[1]四川大学华西医院血液科血液病研究室,成都610041

出　　处：《华西医学》2011年第4期521-523,共3页West China Medical Journal

摘　　要：目的研究以万珂为主化学疗法方案提高多发性骨髓瘤初发患者自体外周血造血干细胞采集的作用。方法回顾性分析2006年1月2010年11月4例初发多发性骨髓瘤患者在万珂治疗后自体外周血造血干细胞采集的临床资料。疗效判定依据国际骨髓瘤工作组2006年疗效判断标准。结果经过万珂为主化学疗法方案治疗3~6个疗程（平均4个疗程）后,3例获得CR及以上疗效,均顺利实施了外周血造血干细胞采集;3例采集次数仅1次,1例为2次;平均获得CD34＋细胞8.43×106/kg,完全达到采集要求。结论万珂为主化学疗法方案起效快、疗效好,可以提高初发多发性骨髓瘤患者的干细胞采集率。Objective To explore the improvement of autologous stem cells collection in patients with newly-diagnosed multiple myeloma after Velcade-based chemotherapy.Methods The clinical data of four patients with multiple myeloma who underwent Velcade-based chemotherapy between January 2006 and November 2010 were retrospectively analyzed.The therapeutic effect was observed.Results After 3-6 courses（mean 4 courses） of Velcade-based chemotherapy,3 patients obtained complete remission（CR） and above response,and the sufficient peripheral blood hematopoietic stem cells were collected successfully.The peripheral blood hematopoietic stem cells were collected once in three patients and twice in one patient.Sufficient number of hematopoietic stem cells（mean CD34 positive-cell 8.43×106/kg） were collected which fully met the collection requirements.Conclusion Velcade-based chemotherapy has advantages of fast action and good therapeutic effect,which can improve the collection of autologous stem cells in patients with newly-diagnosed multiple myeloma.

关 键 词：多发性骨髓瘤 万珂 化学疗法 造血干细胞 

分 类 号：R733.3[医药卫生—肿瘤]